Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas. A. C. Mita, et al. J Clin Oncol. 2008; NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Nicholson B, et al. Anticancer Drugs. 2006 Jan;;17(1):25-31. The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.